Current disease status-First occurrence of the lymphoma Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the lymphoma Posts on Medivizor

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.

Evaluating the effectiveness and safety of brentuximab vedotin plus nivolumab consolidation therapy after autologous hematopoietic stem-cell transplantation in patients with high-risk classic Hodgkin lymphoma.

Posted by on Aug 27, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of brentuximab vedotin (BV; Adcetris) plus nivolumab (Opdivo) consolidation therapy after autologous hematopoietic stem-cell transplantation (HSCT) in patients with high-risk relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL). The data showed that the BV plus nivolumab combination...

Read More

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Posted by on Jun 11, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) before stem cell transplantation. The data showed that pembrolizumab was effective and safe with manageable side effects in these patients. Some background...

Read More

How are survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: A quality of life study

How are survivors 1 year after the diagnosis of diffuse large B-cell lymphoma: A quality of life study

Posted by on Dec 5, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The authors investigated the health-related quality of life (HRQoL) 1 year after the diagnosis of diffuse large B-cell lymphoma (DLBCL). The study found that HRQoL is affected differently in women and men survivors of DLBCL 1 year after diagnosis and that aspects of HRQoL need to be addressed and managed in these...

Read More

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Combining brentuximab vedotin and bendamustine for the treatment of children with relapsed/refractory Hodgkin Lymphoma

Posted by on Nov 7, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to evaluate brentuximab vedotin (BV; Adcedris) and bendamustine (Treanda) treatment in pediatric patients with relapsed/refractory (r/r) Hodgkin Lymphoma (HL).  This study concluded that this treatment combination was safe and effective in these patients.   Some background HL is a common cancer...

Read More

Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL

Evaluating the effectiveness of lenalidomide plus rituximab for patients with recurrent or hard-to-treat DLBCL

Posted by on Jul 11, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of lenalidomide (Revlimid) plus rituximab (Rituxan) for patients with diffuse large B-cell lymphoma (DLBCL) that came back or stopped responding to treatment. This study concluded that this treatment showed some effectiveness, but adding other agents may improve outcomes for these...

Read More

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Does combining brentuximab vedotin with chemotherapy reduce the risk of consolidative radiotherapy for patients with early-stage unfavorable-risk Hodgkin lymphoma?

Posted by on Jun 6, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated whether brentuximab vedotin (Adcedris; BC) + AVD (doxorubicin, vinblastine, and dacarbazine) chemotherapy combination resulted in a reduction or elimination of consolidative radiotherapy in early-stage unfavorable-risk Hodgkin lymphoma (HL). The data showed that the BV+AVD combination with and without...

Read More

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Evaluating the safety and effectiveness of brentuximab vedotin for children with high-risk Hodgkin lymphoma.

Posted by on May 23, 2021 in Hodgkin's lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of incorporating brentuximab vedotin (BV; Adcetris) as a substitution for vincristine in the OEPA (vincristine, etoposide, prednisone, doxorubicin) or COPD (cyclophosphamide, vincristine, prednisone, dacarbazine) chemotherapy regimen in children with high-risk classical...

Read More

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Evaluating the effectiveness and safety of inotuzumab ozogamicin for patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma

Posted by on Apr 18, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effectiveness and safety of inotuzumab ozogamicin (Besponsa; INO) in patients with relapsed/refractory (r/r) acute lymphocytic leukemia (ALL) and non-Hodgkin lymphoma (NHL). The data showed that the treatment had good effectiveness and manageable side effects for these patients. Some background A high number...

Read More

How effective is idarubicin-substituted BEAC (IEAC) as a conditioning regimen for patients with B-cell non-Hodgkin’s lymphoma undergoing ASCT?

How effective is idarubicin-substituted BEAC (IEAC) as a conditioning regimen for patients with B-cell non-Hodgkin’s lymphoma undergoing ASCT?

Posted by on Apr 4, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the BEAC (BCNU, etoposide, cytarabine, and cyclophosphamide) and IEAC (idarubicin, etoposide, cytarabine, and cyclophosphamide) regimens before autologous stem cell transplantation (ASCT) in patients with relapsed/refractory (r/r) and aggressive B-cell non-Hodgkin lymphoma (NHL). The study found that IEAC regimen...

Read More

Treatment of primary central nervous system lymphoma: high-dose methotrexate alone or with additional therapy?

Treatment of primary central nervous system lymphoma: high-dose methotrexate alone or with additional therapy?

Posted by on Feb 27, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell The aim of this study was to evaluate high-dose (HD) methotrexate (MTX; Trexall) alone and in combination with other therapies for the treatment of primary central nervous system (CNS) lymphoma (PNCSL). The study found that HD-MTX in combination with other chemotherapies was most effective for these patients. Some background...

Read More

Evaluating outcomes for patients with follicular lymphoma after prolonged rituximab maintenance therapy

Evaluating outcomes for patients with follicular lymphoma after prolonged rituximab maintenance therapy

Posted by on Feb 6, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated different rituximab schedules in patients with follicular lymphoma (FL) and reported their long-term treatment outcomes. The data showed that rituximab treatment alone on a standard schedule improves the long-term outcomes of these patients. Some background Follicular lymphoma (FL) is a type of non-Hodgkin...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2023 Medivizor